Guardant Health Stock Forecast, Price & News

Guardant Health (NASDAQ:GH) Frequently Asked Questions

Is Guardant Health a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health or view top-rated stocks.

What stocks does MarketBeat like better than Guardant Health?

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Guardant Health?

Guardant Health saw a increase in short interest in the month of August. As of August 13th, there was short interest totaling 3,810,000 shares, an increase of 16.2% from the July 29th total of 3,280,000 shares. Based on an average daily volume of 884,400 shares, the short-interest ratio is presently 4.3 days. Currently, 4.0% of the shares of the company are short sold.
View Guardant Health's Short Interest.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Guardant Health.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) issued its earnings results on Thursday, August, 5th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.09. The firm had revenue of $92.10 million for the quarter, compared to analysts' expectations of $84.63 million. Guardant Health had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 116.99%.
View Guardant Health's earnings history.

How has Guardant Health's stock been impacted by COVID-19?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GH stock has increased by 104.0% and is now trading at $128.40.
View which stocks have been most impacted by COVID-19.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $360 million-$370 million, compared to the consensus revenue estimate of $367.97 million.

What price target have analysts set for GH?

12 brokers have issued twelve-month price objectives for Guardant Health's stock. Their forecasts range from $135.00 to $190.00. On average, they expect Guardant Health's stock price to reach $168.64 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts' price targets for Guardant Health or view top-rated stocks among Wall Street analysts.

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:

• Helmy Eltoukhy, Chairman & Co-Chief Executive Officer (LinkedIn Profile)
• AmirAli H. Talasaz, President, Co-Chief Executive Officer & Director
• Michael Bell, Chief Financial Officer
• Darya Chudova, Senior Vice President-Technology
• Kumud Kalia, Chief Information Officer

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Guardant Health's key competitors?

Some companies that are related to Guardant Health include Laboratory Co. of America (LH), Quest Diagnostics (DGX), Natera (NTRA), Invitae (NVTA), Elekta AB (publ) (EKTAY), Veracyte (VCYT), CareDx (CDNA), Fulgent Genetics (FLGT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), RadNet (RDNT), Genetron (GTH), DermTech (DMTK), Personalis (PSNL) and Renalytix AI (RNLX).
View all of GH's competitors.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.52%), FMR LLC (5.57%), BlackRock Inc. (5.46%), Morgan Stanley (4.19%), Clearbridge Investments LLC (3.36%) and Coatue Management LLC (2.63%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman and Timothy P Eckersley.
View institutional ownership trends for Guardant Health.

Which major investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Morgan Stanley, Nuveen Asset Management LLC, Franklin Resources Inc., Invesco Ltd., First Trust Advisors LP, and Rhenman & Partners Asset Management AB. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health or view top insider-selling stocks.

Which major investors are buying Guardant Health stock?

GH stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Macquarie Group Ltd., Coatue Management LLC, Light Street Capital Management LLC, Vanguard Group Inc., Marshall Wace North America L.P., Clearbridge Investments LLC, and RTW Investments LP.
View insider buying and selling activity for Guardant Health or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $128.40.

How much money does Guardant Health make?

Guardant Health has a market capitalization of $13.01 billion and generates $286.73 million in revenue each year. The company earns $-253,780,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How many employees does Guardant Health have?

Guardant Health employs 864 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

Where are Guardant Health's headquarters?

Guardant Health is headquartered at 505 PENOBSCOT DR., REDWOOD CITY CA, 94063.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at (855) 698-8887 or via email at [email protected].